IB1001 (N-acetyl-L-leucine)
Niemann-Pick disease type C (NPC)
Phase 3Active
Key Facts
About IntraBio
IntraBio is a clinical-stage biotech developing IB1001 (N-acetyl-L-leucine), an oral modified amino acid, for rare neurological disorders. Its lead program for Niemann-Pick disease type C (NPC) has reported positive Phase III results, and the company has achieved its first FDA approval with AQNEURSA™ (levacetylleucine) for an undisclosed indication. The company leverages a scientific foundation from key academic institutions and is advancing a pipeline targeting common neurological disorders and healthspan.
View full company profileTherapeutic Areas
Other Niemann-Pick disease type C (NPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Nizubaglustat (RAINBOW/NAVIGATE) | Azafaros | Phase 3 |
| Arimoclomol (MIPLYFFA) | Zevra Therapeutics | Marketed |
| Arimoclomol | Zevra Therapeutics | Filed |